Longeveron Inc.
0.8881-0.04 (-4.39%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · LGVN · USD
Key Stats
Market Cap
18.70MP/E (TTM)
3.55Basic EPS (TTM)
0.25Dividend Yield
0%Recent Filings
8-K
Nasdaq compliance warning issued
Longeveron Inc. received a Nasdaq notice on September 22, 2025, for failing the $1.00 minimum bid price requirement over 30 consecutive business days, triggering a 180-day compliance window until March 23, 2026. The company plans to monitor its stock price and explore options to regain listing eligibility, but faces risks of delisting if the bid drops to $0.10 or below for ten days. No assurance of success.
8-K
ATM offering for $10.7M
Longeveron Inc. entered an at-the-market offering agreement with H.C. Wainwright & Co. on September 19, 2025, enabling sales of up to $10,700,000 in Class A common stock through Nasdaq or negotiated deals. Proceeds will fund clinical development of laromestrocel for Hypoplastic Left Heart Syndrome, Alzheimer's, and Pediatric Dilated Cardiomyopathy, plus working capital. No sales are guaranteed. Dilution looms for shareholders.
8-K
Longeveron CEO steps down
Longeveron Inc. announced on August 27, 2025, that CEO Wa'el Hashad stepped down immediately to pursue other opportunities, prompting the board to appoint Than Powell, current Chief Business Officer, as interim CEO effective September 4, 2025, and Dr. Joshua Hare as Executive Chairman. Powell, with over 25 years in pharma and biotech, will receive a $500,000 base salary and equity grants. This shift bolsters leadership continuity amid pivotal trials for stem cell therapy laromestrocel, including full enrollment in the Phase 2b HLHS study with top-line results expected in 2026. Yet risks from clinical uncertainties loom large.
8-K
Q2 results and trial milestones
Longeveron announced Q2 2025 results, reporting $0.7 million in revenues for the first half, down 31% from $1.0 million last year due to lower clinical trial and manufacturing demand, while net loss widened to $10.0 million from $7.5 million amid rising R&D and G&A expenses. The company hit full enrollment in its pivotal Phase 2b ELPIS II trial for laromestrocel in HLHS, with top-line data expected Q3 2026 and potential BLA filing late 2026 if positive. FDA cleared an IND for pediatric DCM, enabling a Phase 2 trial start in H1 2026. Cash stands at $10.3 million, funding operations into Q1 2026, but financing needs loom large.
10-Q
Q2 FY2025 results
Longeveron posted Q2 revenue of $316K, down 32% y/y from $468K, as contract manufacturing softened while clinical trial fees held steady at $298K; gross profit slipped to $146K from $344K. Operating loss widened to $5.4M from $3.5M, driven by 72% higher R&D spend on BLA-enabling CMC work and 22% more G&A, yielding a net loss of $5.0M or $0.33/share on 15.0M diluted shares—sharper than last year's $3.4M or $1.83/share on 6.5M shares, with no material anti-dilution noted. Cash burned $8.9M YTD to $10.3M, funding ops into Q1 2026 post-August's $4.5M net raise; free cash flow not disclosed in the 10-Q. ELPIS II trial fully enrolled, eyeing BLA in late 2026 if positive. Yet competition in regenerative therapies could stall progress.
ANVS
Annovis Bio, Inc.
2.20+0.10
ELVN
Enliven Therapeutics, Inc.
22.65+1.10
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
FBLG
FibroBiologics, Inc.
0.39-0.03
GERN
Geron Corporation
1.23-0.05
LBRX
LB Pharmaceuticals Inc
15.65-0.92
RMTG
Regenerative Medical Technology
0.05+0.00
SEOVF
SERNOVA BIOTHERAPEUTICS INC.
0.12+0.00
TELO
Telomir Pharmaceuticals, Inc.
1.50-0.01
VCEL
Vericel Corporation
34.88-1.95